Sacituzumab Govitecan: First Approval | SpringerLink
Sacituzumab govitecan-hziy | New Drug Approvals
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial - Annals of Oncology
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan - ScienceDirect
Trodelvy for the Treatment of Advanced Triple-Negative Breast Cancer
Antibody–Drug Conjugates | Encyclopedia
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan - ScienceDirect
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond | SpringerLink
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments | SpringerLink
Form 8-K IMMUNOMEDICS INC For: Jun 01
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan,European Journal of Medicinal Chemistry - X-MOL
Basic information about sacituzumab govitecan
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer - National Cancer Institute
Role of Trop-2 as an Actionable Biomarker in Solid Tumors
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer | Biochempeg
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index | Clinical Cancer Research
Emerging Novel Therapeutics in Triple-Negative Breast Cancer | SpringerLink
Pharmaceuticals | Free Full-Text | Antibody–Drug Conjugates: The Last Decade | HTML
DNA damaging agent-based antibody-drug conjugates for cancer therapy
TRODELVYᵀᴹ (sacituzumab govitecan-hziy) | Mechanism of Action
Mechanism of action of ADCs | Download Scientific Diagram
Immunomedics Competitor Threatens To Leapfrog Approval With Breakthrough Therapy Designation (OTCMKTS:CYDY) | Seeking Alpha
ESMO 2020: Sacituzumab Govitecan Significantly Extends Overall Survival in Patients with mTNBC - Onco'Zine
Immunomedics triple negative breast cancer ADC drug rejected by FDA in the United States – Creative Biolabs ADC Blog
